About Lundbeck
Lundbeck is a company based in Copenhagen (Denmark) founded in 1915. The company has 5,710 employees as of December 31, 2024. Lundbeck has completed 8 acquisitions, including Abide Therapeutics, Alder and Alder Biopharmaceuticals. Lundbeck operates in a competitive market with competitors including Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
- Headquarter Copenhagen, Denmark
- Employees 5710 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name H. Lundbeck A/S Class A
-
Annual Revenue
$3.83 B (USD)10.41as on Dec 31, 2025
-
Net Profit
$501.85 M (USD)1.56as on Dec 31, 2025
-
EBITDA
$1.36 B (USD)40.42as on Dec 31, 2025
-
Latest Funding Round
$338.46 K (USD), Grant
Mar 01, 2019
-
Investors
European Union
& 1 more
-
Employee Count
5710
as on Dec 31, 2024
-
Investments & Acquisitions
Abide Therapeutics
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lundbeck
Lundbeck is a publicly listed company on the OMXCOP with ticker symbol HLUN_A in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Lundbeck
Unlock access to complete
Unlock access to complete
Leadership Team
121 people
Software Development Team
85 people
Sales and Marketing
47 people
Finance and Accounting
39 people
Human Resources and Administration
38 people
Product Management Team
35 people
Senior Team
34 people
Legal and Compliance
24 people
Unlock access to complete
Funding Insights of Lundbeck
Investors in Lundbeck
Lundbeck has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and IFU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Lundbeck
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lundbeck
Lundbeck has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Abide Therapeutics, Alder and Alder Biopharmaceuticals.
Investment portfolio details for Lundbeck
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutic solutions for rare neurological diseases are developed.
|
Locked | Locked | 2020 | Locked | |
|
Parkinson's drugs targeting mGluR3 and mGluR4 receptors are developed.
|
Locked | Locked | 2012 | Locked | |
|
Serine hydrolase inhibitors are developed for pain management.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Lundbeck
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lundbeck
Detailed financials for Lundbeck
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lundbeck Comparisons
Peer comparison for Lundbeck
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lundbeck
Lundbeck operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapies for psychosis and cognitive impairment are developed.
|
Detailed competitors of Lundbeck
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lundbeck
Complete news archive for Lundbeck
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lundbeck
Lundbeck was founded in 1915 and raised its 1st funding round 96 years after it was founded.
Lundbeck is headquartered in Copenhagen, Denmark.
As of Dec 31, 2024, the latest employee count at Lundbeck is 5,710.
Annual revenue of Lundbeck is $3.83B as on Dec 31, 2025.
The company was founded in 1915 in Copenhagen, Denmark, and operates within the pharmaceutical sector. Emphasis is placed on developing treatments for central nervous system disorders. The lead product, Eptinezumab, is a monoclonal antibody used for migraine and cluster headache management. A research pipeline is pursued for depression, schizophrenia, Alzheimers disease, Parkinsons disease, and insomnia, with operations centered in Europe and global outreach.
Lundbeck's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Yes, Lundbeck is publicly traded on OMXCOP under the ticker symbol HLUN_A.
Lundbeck has made 8 acquisitions, including Abide Therapeutics, Alder, and Alder Biopharmaceuticals.
Lundbeck has 2 investors. Key investors include European Union, and IFU.
The ticker symbol of Lundbeck is HLUN_A on OMXCOP.